Is There a Generic for Wegovy?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Wegovy (semaglutide). The Orange Book shows its last listed patent expires February 17, 2041 and its last listed exclusivity ends December 22, 2028.

Run it in Rivvi

Map Wegovy and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Wegovy products in the Orange Book

Wegovy products and approved generics
Form and route	Strength	Brand status	Brand TE	Generic TE codes
solution, subcutaneous	0.25MG/0.5ML (0.25MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	0.25MG/0.5ML (0.25MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	0.5MG/0.5ML (0.5MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	0.5MG/0.5ML (0.5MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	1.7MG/0.75ML (1.7MG/0.75ML)	Marketed (Rx)	None	None
solution, subcutaneous	1.7MG/0.75ML (1.7MG/0.75ML)	Marketed (Rx)	None	None
solution, subcutaneous	1MG/0.5ML (1MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	1MG/0.5ML (1MG/0.5ML)	Marketed (Rx)	None	None
solution, subcutaneous	2.4MG/0.75ML (2.4MG/0.75ML)	Marketed (Rx)	None	None
solution, subcutaneous	2.4MG/0.75ML (2.4MG/0.75ML)	Marketed (Rx)	None	None
tablet, oral	1.5MG	Marketed (Rx)	None	None
tablet, oral	25MG	Marketed (Rx)	None	None
tablet, oral	4MG	Marketed (Rx)	None	None
tablet, oral	9MG	Marketed (Rx)	None	None

NDA 215256, 218316, held by NOVO NORDISK INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Wegovy patents

Patents listed for Wegovy
Patent	Expires	Covers	Use code	NDA
8536122	March 20, 2026	Drug substance, Drug product	None	215256
8129343	December 5, 2031	Drug substance, Drug product	None	215256
11382957	December 16, 2031	Drug product	None	218316
9278123	December 16, 2031	Drug product	U-4389	218316
11033499	June 19, 2033	Drug product	U-4496	218316
9764003	June 21, 2033	Method of use	U-3161	215256
12239739	May 2, 2034	Method of use	U-4388	218316
10278923	May 2, 2034	Method of use	U-4389	218316
12569543	April 28, 2037	Method of use	U-4443	215256
12214017	August 24, 2038	Drug product	U-3162	215256
11752198	August 24, 2038	Drug product	U-3162	215256
10888605	August 24, 2038	Drug product	U-3162	215256
12551536	October 10, 2038	Method of use	U-4418	215256
12029779	October 10, 2038	Method of use	U-3162	215256
12396953	February 1, 2039	Drug product	U-4387	218316
11833248	February 1, 2039	Drug product	U-4387	218316
11478533	May 13, 2040	Method of use	U-3861	215256
11318191	February 17, 2041	Drug product	U-3162	215256
11318191	February 17, 2041	Drug product	U-4443	215256
11318191	February 17, 2041	Drug product	U-4560	215256

Wegovy exclusivity

Exclusivity listed for Wegovy
Code	Meaning	Expires	NDA
D-190	New dosing schedule	July 21, 2026	215256
I-935	New indication	March 8, 2027	215256
I-973	New indication	August 15, 2028	215256
NP	New product	December 22, 2028	218316

Wegovy NDC codes

Questions

Is there a generic for Wegovy?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Wegovy (semaglutide). The Orange Book shows its last listed patent expires February 17, 2041 and its last listed exclusivity ends December 22, 2028.

What is the generic name for Wegovy?

The active ingredient in Wegovy is semaglutide, per the FDA Orange Book.

When does the Wegovy patent expire?

The last patent listed for Wegovy in the Orange Book expires February 17, 2041. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.